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We have examined the relationship between coreceptor utilization and 
sensitivity to neutralization in a primary isolate (PI) of human immunodeficiency 
virus (HIV) and its T-cell line adapted (TCLA) derivative. We determined that 
adaptation of the PI virus 168P results in the loss of the unique capacity of PI 
viruses to utilize the CCR5 coreceptor, and in the acquisition by the TCLA 168C 
virus of sensitivity to neutralization by V3-directed monoclonal antibodies (MAbs). 
In experiments wherein infection by 168P is directed via either the CCR5 or 
CXCR4 pathway, we demonstrate that the virus, as well as pseudotyped virions 
bearing a molecularly cloned 168P envelope protein, remain refractory to 
neutralization by MAbs 257-D, 268-D, and 50.1 regardless of the coreceptor 
utilized. This study suggests that coreceptor utilization is not a primary 
determinant of differential neutralization sensitivity in PI and TCLA virus.
Current recombinant HIV gp120 protein vaccine candidates fail to elicit 
antibodies capable of neutralizing infectivity of primary patient isolates. Here, 
novel ‘fusion-competent’ HIV vaccine immunogens are discussed that capture 
the transient envelope-CD4-coreceptor structures which arise during HIV binding 
and fusion. In a transgenic mouse immunization model, these formaldehyde- 
fixed whole cell vaccines elicited antibodies capable of neutralizing infectivity of 
23 of 24 primary HIV isolates form diverse geographical locations and genetic 
clades A-E. Development of these novel fusion-dependent immunogens may 
lead to a broadly effective HIV isolates.
We have developed a host range system to measure the mutation frequency of 
feline immunodeficiency virus (FIV), the feline homologue of HIV-1. When wild- 
type FIV was grown in the presence of a known mutagen, 5-bromo-2’- 
deoxyuridine (BUdR), a dose-dependent increase of host range mutants was 
detected. Using this system, we have evaluated the effects of antiviral drugs 
upon the mutation frequency of FIV. Subinhibitory concentrations of 3’-azido-3’- 
deoxythymidine (AZT), the most common antiviral drug used in AIDS 
chemotherapy, increased the mutation frequency of FIV in a dose-dependent 
manner. Two other antivirals, 2’,3’-dideoxyinosine (ddl) and 2 \3 ’-dideoxycytidine 
(ddC) did not show this effect.
Director: Jack H. Nunberg
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Chapter 1 
Introduction
Human immunodeficiency virus type 1 (HIV-1) is the etiological agent of 
the acquired immune deficiency syndrome (AIDS) (1,2). This retrovirus has 
caused a worldwide epidemic and the WHO (World Health Organization) has 
estimated that 40 million people will be infected by the year 2000 (3). To date, 
there is no cure for HIV infection, limited effective therapy, and no protective 
vaccine. Current vaccine strategies have focused on the envelope glycoprotein 
of HIV, the viral protein that mediates the early binding and entry events that 
ultimately lead to infection. However, all vaccine candidates thus far have failed 
to elicit antibodies capable of neutralizing infection by primary isolates (Pis), i.e. 
viruses obtained from infected individuals (4-7).
Synthesis and Processing of HIV Envelope Glycoprotein
The synthesis and processing of the HIV envelope glycoprotein occurs in 
the secretory pathway of the infected host cell. The envelope protein is originally 
synthesized as a precursor polyprotein, which is cotranslationally transferred into 
the lumen of the endoplasmic reticulum (ER). During this time, the precursor 
protein is modified by cellular enzymes by adding high-mannose units to the 
protein. This yields an HIV precursor glycoprotein with a molecular mass of 160 
kd (gp160) (8). While in the ER lumen, intramolecular disulfide bonds are formed 
to produce a folded monomer of gp160 (9), which then associates into trimeric 
complexes (10). After oligomerization, the envelope complexes are
i
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transferred to the Golgi apparatus where the carbohydrate moieties are 
terminally modified to produce complex/hybrid carbohydrate chains (11).
While in the Golgi apparatus, the gp160 precursors are cleaved into the 
noncovalently linked gp120 and gp41 subunits, forming the mature envelope 
glycoprotein (12). The cleavage is mediated by the cellular serine proteases 
furin and PC7 (13-15). These proteases act on each chain of the gp160 
oligomer and cleave at a highly conserved basic region that defines the C- 
terminus of gp120 and the N-terminus of gp41. Cleavage of the precursor 
protein is thought to induce a conformational change that releases gp41 from the 
C-terminus of gp120 and buries the N-terminal hydrophobic fusion peptide of 
gp41 within the oligomer (16-18). After cleavage, the mature oligomers are 
transported from the Golgi apparatus to the plasma membrane of the host cell 
via a cellular vesicle transport system (19).
The HIV-1 Envelope Glycoprotein
HIV envelope-mediated binding and entry is the initial step in the 
replication process of the virus. A series of molecular interactions between the 
host cell and virus is initiated by the binding of the viral envelope glycoprotein to 
the cellular CD4 molecule of CD4+ T lymphocytes and cells of the monocyte- 
macrophage lineage (20-25). The envelope protein consists of the surface 
subunit, gp120, which is noncovalently associated to the transmembrane 
subunit, gp41 (26,27). The gp120/gp41 heterodimer assembles into trimeric 
complexes to form the functional HIV envelope protein (11,28-31).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The gp120 subunit of the HIV envelope glycoprotein is a highly 
glycosylated, hydrophilic protein located on the surface of the virion and plasma 
membrane of infected cells. HIV gp120 has 24 potential sites for N-linked 
glycosylation (Asn-X-Ser/Thr), 13 of which are highly conserved among different 
HIV-1 viral isolates (32,33). The amino acid sequence comparison of gp120 
from HIV-1, HIV-2, and SIV isolates also reveals that there are 18 highly 
conserved cysteine residues. The conservation of these amino acids suggests 
that disulfide bonds are essential to the structure and function of this protein. 
The secondary structure of the envelope glycoprotein and the nine putative 
disulfide bonds found in gp120 are depicted in Fig. 1 (32,34).
F icL l : The predicted folding patterns of HIV-1 envelope glycoprotein. 
Hypervariable domains of gp120 are designated V1-V5. Regions of gp41 are as 
follows: F, fusion peptide; TM, transmembrane domain.
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Despite the conservation of the overall secondary structure of the 
envelope glycoprotein, all isolates of HIV-1, HIV-2, and SIV have extensive 
sequence heterogeneity throughout the envelope gene (35). There is up to 50% 
variation in the envelope amino acid sequence in HIV-1 strains, although other 
parts of the genome are relatively conserved (36). The gp120 subunit contains 
five variable loops, designated V1-V5, which are separated by conserved 
regions. It has been previously shown that the envelope protein contains the 
determinants for cell tropism, cytopathic effect, and coreceptor utilization. The 
variable V3 loop has been implicated as a key player in these determinants. 
Changes in the V3 loop can affect cell tropism by altering the ability of viral 
isolates to grow in primary monocyte-derived macrophages and T cell lines 
(5,37-42). This variable region is also a major determinant of cytopathic effects, 
such as syncytium formation in primary lymphocyte cultures (43-45), and has 
been implicated in differences in neutralization sensitivity of viral isolates to 
soluble CD4 (sCD4) (46,47) and to V3-directed monoclonal antibodies (mAbs) 
(48-50). Recently, the V3 loop has also been found to play a role in the 
differential utilization of coreceptors (51-54).
The gp120 subunit is anchored to the surface of virions or infected cells 
through noncovalent interaction with the transmembrane subunit, gp41. Gp41 
traverses the lipid bilayer once and serves as the anchor of the envelope 
glycoprotein. Mutational analysis reveals that both the N-terminus and C- 
terminus of gp120 mediate the noncovalent contact between gp120 and gp41 
(26,42,55,56). Although, the contacts mediated by gp41 are yet to be identified,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
a disulfide loop in the N-terminus of gp41 is believed to form a knob that fits into 
a pocket in the gp120 subunit (57,58).
The N-terminus of gp41 has a hydrophobic region of approximately 20 
amino acids which is required for fusion of the viral and cell membrane, and is 
termed the fusion peptide (26,59,60). Near the C-terminal end of gp41 resides 
an additional hydrophobic domain that spans the cell or viral membrane, serving 
as an anchor for the glycoprotein heterodimer (61). The domain between these 
two hydrophobic regions, the ectodomain, is highly conserved. The ectodomain 
is proposed to form a structure similar to a leucine zipper motif and is believed to 
form a coiled-coil structure, which facilitates the insertion of the fusion peptide 
into the target cell membrane upon activation (62).
CD4 and Coreceptor Binding
It has long been known that the cellular CD4 molecule is the high affinity 
receptor to which the HIV envelope glycoprotein binds to initiate envelope- 
mediated membrane fusion (22,23). However, CD4 binding alone is not 
sufficient for HIV envelope-mediated fusion and infection of the host cell. When 
nonhuman cells were transfected to express human CD4, HIV-1 could not 
mediate envelope fusion and/or infection (24,63-65). This suggested that there 
was a coreceptor involved in HIV binding and entry.
Recently, HIV-1 coreceptors, cellular molecules that act in conjunction 
with the CD4 molecule to allow envelope-mediated fusion, have been elucidated 
(REF). The HIV-1 coreceptors are members of the chemokine receptor family
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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and are seven transmembrane-segment G-protein-coupled molecules that 
normally function as receptors to the a- and P-chemokines. Chemokines are 
small molecules involved in the chemotactic recruitment of selected leukocytes 
to sites of inflammation (66,67). With the discovery of these coreceptors has 
come the understanding that various isolates of HIV-1 utilize different 
coreceptors for binding and entry. The commonly used T-cell line-adapted 
(TCLA) isolates utilize the CXCR4 ct-chemokine receptor exclusively (68,69), 
whereas Pis of HIV-1 that are monocytropic/non-syncytium-inducing (NSI) utilize 
only the P-chemokine receptor CCR5. HIV-1 Pis that are 
lymphocytropic/syncytium-inducing (SI) are able to utilize either CXCR4 or CCR5 
(52,70-74).
PI and TCLA Viruses
Pis of HIV are obtained by limited cultivation of patient peripheral blood 
mononuclear cells or patient plasma with uninfected cells (1,75). There is a 
spectrum of biological phenotypes of these PI viruses. SI isolates infect and 
induce syncytia formation in peripheral blood lymphocytes (PBLs). SI isolates 
can also replicate in the MT2 T-cell line, but are unable to replicate in less 
permissive T-cell lines, such as H9 cells (76,77). In contrast, NSI isolates are 
only able to replicate in primary cells, and unlike the SI isolates, are able to 
replicate in primary monocyte-derived macrophages (78). Transitional 
intermediates of these two biological phenotypes of the primary isolates have 
been detected in vivo (79). During active infection, NSI isolates predominate
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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during the early/asymptomatic stage while SI isolates slowly arise from the NSI 
population (79,80). The emergence of SI isolates during infection is associated 
with progression to AIDS (80). The spectrum of the biological phenotypes can 
also be extended to TCLA isolates (46), and the variation of these phenotypes 
may reflect the continuum of the multiple interactions between the virus and cell 
during the early binding and entry events of infection.
PI and TCLA viruses of HIV not only differ in coreceptor utilization and cell 
tropism, but also exhibit a marked difference in neutralization sensitivities. PI 
viruses exhibit decreased sensitivities to in vitro neutralization by sCD4 (5,7,81- 
83), sera from infected individuals (5,6,84,85), monoclonal antibodies (48-50), 
and HIV vaccine sera (4-7).
During adaptation of PI viruses to growth in established T-cell lines, the 
change in cell tropism is accompanied by changes in both neutralization 
sensitivity and cytopathic effect. The current generation of vaccines comprised 
of recombinant gp120 (rgp120) subunits elicits antibodies that potently neutralize 
infection of homologous TCLA viruses (86-89), however PI viruses are refractory 
to in vitro neutralization by the vaccine sera. The reason behind the universal 
failure of rgp120 vaccine sera to neutralize PI viruses remains elusive. However, 
the structural and/or functional differences between PI and TCLA viruses in the 
process of binding and entry may hold some of these answers.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Conformational Changes Mediated by Binding and Entry Events
During binding and entry, the HIV envelope protein undergoes a series of 
complex interactions and conformational changes that result in membrane 
fusion. Initially, the envelope complex binds to CD4 and undergoes a 
conformational change that results in an increased exposure of certain antibody 
epitopes, also known as CD4-induced (CD4i) epitopes (90-92). Monoclonal 
antibodies from HIV infected individuals that are specific for the CD4i epitopes 
have been isolated and been found to neutralize a range of PI and TCLA viruses 
(93,94). During the binding and entry process, the dissociation (or shedding) of 
the gp120 from the gp41 subunit of the envelope complex increases (95-99). 
Along with conformational changes occurring in the viral envelope complex upon 
CD4 binding, there also are conformational changes observed in the CD4 
receptor (100,101). These changes in CD4 and envelope facilitate the 
subsequent interactions with the coreceptor, forming a trimolecular complex 
(53,54,102,103). The conformational changes in the envelope-CD4-coreceptor 
complex mediate the exposure and activation of the gp41 fusion peptide, and 
ultimately lead to the fusion of the opposed virus and cell membranes 
(26,104,105).
During the process of envelope-mediated fusion, a number of neutralizing 
epitopes are exposed, albeit transiently. As mentioned above, a number of 
human mAbs from infected individuals recognize CD4i epitopes, and are able to 
neutralize a diverse range of PI and TCLA viruses (93,94). It has also been
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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shown that sera from infected individuals typically neutralize Pis with frequencies 
of 30-50%, although the results vary for individual sera and individual viruses 
(106-108). This indicates that there is an inherent difference in the antibodies 
elicited from infected individuals as compared to the antibodies elicited from 
rgp120 vaccines.
Proposed Work
The following studies explore the relationship between neutralization 
sensitivity and coreceptor utilization, especially in regards to the changes that 
accompany adaptation of Pis to growth in T-cell lines. We hypothesize that Pis 
are refractory to neutralization as a result of the unique ability to utilize the CCR5 
coreceptor, rather than CXCR4. To test this hypothesis, we examine a well- 
characterized SI primary virus, 168P, under experimental conditions where 
infection is directed via the CXCR4 and CCR5 pathway to determine whether 
coreceptor pathway is a determinant of neutralization sensitivity.
It has been previously shown that PI viruses are refractory to neutalization 
by rgp120 vaccine sera. This vaccine strategy incorporates a static envelope as 
the immunogen, i.e. an envelope that is not interacting with CD4 and coreceptor. 
In an infected individual, however, the immune system is responding to an 
envelope protein expressed in its native oligomeric conformation and is actively 
participating in the binding and entry process. An active infection, therefore, 
presents the immune system with the transient, fusion-dependent epitopes that 
arise during fusion. We hypothesize that the failure of current rgp120 vaccine
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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strategies is due to the fact that the fusion-dependent epitopes present during an 
active infection are not incorporated into the immunogen. We test this 
hypothesis by formulating a fusion-competent’ vaccine that incorporates a 
functioning envelope interacting with CD4 and coreceptor into the immunogen, 
and determine if this new vaccine strategy can elicit antibodies capable of 
neutralizing primary isolates of HIV.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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29
We have examined the relationship between coreceptor utilization and sensitivity 
to neutralization in a primary (PI) isolate of HIV and its T cell line adapted (TCLA) 
derivative. We determined that adaptation of the PI virus 168P results in the loss 
of the unique capacity of PI viruses to utilize the CCR5 coreceptor, and in the 
acquisition by the TCLA 168C virus of sensitivity to neutralization by V3-directed 
monoclonal antibodies (MAbs). In experiments wherein infection by 168P is 
directed via either the CCR5 or CXCR4 pathway, we demonstrate that the virus, 
as well as pseudotyped virions bearing a molecularly cloned 168P envelope 
protein, remain refractory to neutralization by MAbs 257-D, 268-D, and 50.1 
regardless of the coreceptor utilized. This study suggests that coreceptor 
utilization is not a primary determinant of differential neutralization sensitivity in 
PI and TCLA viruses.
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Although CD4 had long been recognized as the cellular receptor to which 
the human immunodeficiency virus type 1 (HIV) envelope protein binds (9, 21, 
22), it had also been recognized that expression of CD4 alone is insufficient to 
render non-human cells susceptible to HIV infection (4, 5, 22). Similarly, different 
HIV isolates display different abilities to infect CD4-positive human 
macrophages, T lymphocytes, and established T cell lines (31, 32, 35), 
suggesting that additional molecules may be responsible for cell tropism 
specificity. During the past year, cellular molecules that act in conjunction with 
CD4 have been identified as required cofactors for HIV envelope protein- 
mediated binding and entry (1, 6, 10-12, 14). These HIV coreceptors are 
members of the superfamily of seven-transmembrane segment G-protein 
coupled receptors and act primarily as cellular receptors for chemokines.
The discovery of cellular coreceptors for HIV has provided new 
perspectives for understanding these early events in HIV infection (see review 
(2)). Thus, phenotypically distinct isolates of HIV utilize as coreceptors different 
chemokine receptor molecules. Although all primary isolates (PI) of HIV infect 
primary T lymphocytes, some also infect cells of the macrophage lineage (31,
32). These monocytropic isolates utilize the CCR5 chemokine receptor, whose 
natural ligands include the chemokines RANTES, MIP-1aand MIP-ip (1, 6, IQ- 
12). Monocytropic isolates do not induce syncytia in primary lymphocyte culture 
and do not infect established T cell lines (31). During the late course of HIV 
infection, syncytium-inducing (SI) primary viruses often arise from the population 
of monocytropic viruses (31, 32). These SI primary isolates no longer infect
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macrophages, and utilize both CCR5 and another chemokine receptor, CXCR4 
(7, 33, 38). CXCR4, whose natural chemokine ligand is SDF-1 (3, 27), was 
originally identified by Berger and colleagues as the cofactor used by laboratory- 
adapted viruses (14). In fact, the common laboratory viruses (lllb/LAI, LAV, RF) 
are unable to utilize CCR5 coreceptor (1, 6, 10-12), presumably reflecting the 
lack of CCR5 expression in most established T cell lines (1, 13). Although some 
primary isolates utilize additional chemokine receptor molecules, notably CCR3 
and CCR2b (6, 11, 18), the relationship between these coreceptors and viral 
phenotypes is less clear. The ability to utilize CCR5 coreceptor, however, is 
unique to PI viruses.
Paralleling these differences in coreceptor utilization and cell tropism are 
differences in sensitivity to virus neutralization. Although laboratory-adapted 
isolates of HIV can be potently neutralized by sera elicited by recombinant gp120 
protein, primary isolates are largely refractory to neutralization by rgp120 vaccine 
sera (23, 37). Similarly, PI viruses are significantly more resistant than TCLA 
viruses to neutralization by gp120-directed monoclonal antibodies (MAbs) (25,
37) and to inhibition by soluble forms of CD4 (8). We and others have 
demonstrated that neutralization sensitivity develops concomitantly with 
adaptation of PI isolates to persistent growth in established T cell lines (24, 37). 
By studying pedigreed PI and TCLA viruses (168P and 168C, respectively), we 
have shown that adaptation renders the TCLA virus sensitive not only to rgp120 
vaccine sera and CD4 immunoadhesin, but also to MAbs directed to the V3-loop
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of gp120 (37). However, the basis for this increase in neutralization sensitivity 
remains unclear.
In this report, we explore the relationship between neutralization sensitivity 
and coreceptor utilization, especially with regard to changes that accompany 
adaptation. We examined neutralization sensitivity of the well characterized SI 
primary virus 168P under experimental conditions where infection can be 
directed via either the CXCR4 or CCR5 pathway. The pedigreed TCLA derivative 
168C utilizes only CXCR4 and was sensitive to neutralization by the panel of V3- 
directed MAbs used in these studies. However, the primary 168P virus remained 
refractory to neutralization regardless of coreceptor pathway taken. Our findings 
suggest that envelope protein structure, and not coreceptor utilization, is the 
primary determinant of differential neutralization sensitivity in PI and TCLA 
viruses.
Coreceptor utilization by pedigreed PI and TCLA viruses
Cross-sectional surveys of coreceptor use have shown that primary SI 
isolates generally utilize CXCR4 and CCR5 coreceptors, whereas unrelated 
laboratory-adapted isolates utilize only CXCR4 (1, 6, 7,10-12, 14, 33, 38). We 
wished to confirm this trend in a longitudinal study of adaptation. We previously 
described the adaptation of the primary SI virus 168P to persistent growth in the 
FDA/H9 T cell line, and the concomitant development of neutralization sensitivity 
in the resulting TCLA virus 168C (37). In the present study, the ability of these 
pedigreed viruses to utilize specific coreceptors was tested by infection of U87
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human glioma cell lines expressing CD4 (U87-CD4) and the specific coreceptor 
(19). Figure 1 confirms the ability of the SI 168P virus to utilize both CXCR4 and 
CCR5, and the subsequent loss of this latter specificity in the 168C TCLA virus. 
Infection was dependent on coreceptor expression, and both PI and TCLA 
isolates could also utilize CCR3 (data not presented).
In keeping with the determined coreceptor specificity, infection could be 
blocked by addition of coreceptor-specific ligands. Thus, 168P virus infection of 
CCR5-expressing cells was blocked by the CCR5-specific ligands RANTES, 
MIP-1a, and MIP-1{3 (1, 6, 10-12) (Figure 1). Similarly, infection of CXCR4- 
expressing U87-CD4 cells by either virus could be blocked by the CXCR4- 
specific chemokine ligand SDF-1 (3, 27) (data not presented).
Coreceptor pathway and neutralization sensitivity
In previous work, we demonstrated that the PI 168P virus is refractory to 
neutralization by HIV MN gp120 vaccine sera and by several well-characterized 
V3-directed murine MAbs which strongly neutralize infectivity of the TCLA 168C 
virus (37). In the present study, we extended the panel of MAbs to include two 
V3-directed human MAbs: 257-D and 268-D (17). These well-characterized 
human MAbs recognize core epitopes at the crown of the V3 loop of gp120 
(KRIHI and HIGPGR, respectively) - linear sequences known to be present in 
both 168P and 168C envelope proteins (37). These epitope predictions were 
confirmed by gp120-capture ELISA (26) which demonstrated equal binding to 
envelope protein in detergent-solubilized 168P and 168C virions (data not
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presented). Sensitivity to neutralization by these human MAbs was determined in 
a standard assay using phytohemagglutinin (PHA)-activated peripheral blood 
lymphocytes (PBLs) (37). MAbs 257-D and 268-D were found to potently 
neutralize 168C, but failed to neutralize 168P (Figure 2). This pattern of 
neutralization sensitivity is similar to that previously described for the V3-directed 
murine MAb 50.1 (30, 36, 37).
To examine whether sensitivity to neutralization was affected by the 
coreceptor pathway utilized in infection of PBLs, we used inhibitory 
concentrations of CCR5-specific chemokine ligands RANTES, MIP-1a, and MIP- 
1P in order to restrict infection to the CXCR4 pathway. Addition of these 
chemokines to the PBL cultures did not affect virus growth, nor did it affect 
sensitivity to neutralization by the V3-directed human MAbs (Figure 2). To the 
extent that CCR5 blockade was complete, these results suggest that the simple 
availability of the CCR5 pathway is not a factor in the resistance of PI viruses to 
neutralization.
To strengthen this conclusion, we examined neutralization sensitivity in 
human U87-CD4 cell lines expressing only CXCR4 or CCR5. Using this method, 
we confirmed that the SI 168P virus remained refractory to neutralization by 
human MAbs 257-D and 268-D as well as by the murine MAb 50.1, regardless of 
whether infection occurred via CXCR4 or CCR5 (Figure 3). These results 
suggest that availability of the CCR5 pathway is not a primary determinant for 
the resistance of PI viruses to neutralization. The TCLA 168C virus utilized 
CXCR4 only and was sensitive to neutralization.
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Molecularly cloned PI and TCLA envelope genes
In order to understand better the changes that accompany adaptation, 
and those that determine coreceptor utilization and neutralization sensitivity, we 
molecularly cloned the envelope genes of the 168P and 168C viruses. High- 
fidelity XL® PCR (rTth and VentR® DNA Polymerase; PE Applied Biosystems) 
and envA and envN primers (15) were used to amplify a 3.1 kb region of proviral 
DNA encoding the rev and envelope genes. PCR products were isolated by 
unidirectional T/A cloning in the eucaryotic expression vector pCR®3.1-Uni 
(Invitrogen). Expression in pCR®3.1-Uni is driven by the CMV immediate early 
promotor. Multiple clones were isolated from each virus, and transient 
transfection studies in COS-7 cells confirmed the surface expression and fusion 
competence of all clones tested (data not presented).
DNA sequence analysis demonstrated that all 168C molecular clones 
analyzed encoded the three adaptation-associated amino acid changes 
previously identified by PCR sequencing of the 168C virus population (V2: 
I166R, C2:I282N, V3:G318R) (37). Two molecular clones of each 168P and 
168C envelope were subjected to complete DNA sequence analysis (GenBank 
accession numbers AF035532 - AF035534). Molecular clones 168C23 and 
168C60 were identical throughout the envelope gene. Molecular clones 168P5 
and 168P23 differed from each other, and from the previously determined 
sequence, at 4-5 positions distinct from those associated with adaptation. These 
scattered changes within the primary virus quasispecies are considered
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inconsequential at the present level of analysis; the significance of the three 
adaptation-associated changes is under separate investigation.
Functional analysis of these molecularly cloned envelope genes was 
performed by incorporation of the molecularly cloned envelope protein into 
pseudotyped HIV virions. We utilized an envelope-defective provirus derived 
from the molecularly cloned NL4-3 provirus (kindly provided by I.S.Y Chen, 
UCLA). The pNLthyABg/provirus (28) contains a Bgl\l-Bgl\\ deletion within the 
envelope gene and a substitution of the viral nef gene with a cDNA encoding the 
murine thy1.2 cell surface protein. The SV40 ori was subsequently introduced 
into the plasmid to generate pSVNLthyABg/ (V. Planelles, unpublished). 
Cotransfection of COS-7 cells (16, 20) with pSVNLthyABg/provirus and the 
envelope expression plasmid resulted in the production of pseudotyped HIV 
virions. Culture supernatants were harvested 3 days post-transfection, filtered 
and used to infect U87-CD4 cell lines expressing coreceptor. Cells infected by 
virions bearing the complementing envelope protein were identified by 
immunostaining for murine thy1.2 or HIV proteins.
As anticipated, the molecularly cloned envelope proteins recapitulated the 
coreceptor specificity of the parental virus population (legend Figure 4). 
Pseudotyped virions containing 168C60 were only able to infect U87-CD4 cells 
expressing CXCR4, while virions containing 168P23 envelope were able to infect 
U87-CD4 cells expressing either CCR5 or CXCR4. Thus, the viral envelope 
protein appears to be the major, if not sole, determinant of viral coreceptor use. 
These findings also indicate that dual coreceptor use is a direct property of the
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envelope protein complex, and not a result of a mixture of distinct envelope 
proteins in the SI virus population. This conclusion is corroborated by the failure 
of CCR5-specific chemokine ligands to diminish 168P virus production in PBL 
culture (Figure 2).
Finally, we wished to determine the neutralization sensitivity of 
pseudotyped virions containing the molecularly cloned 168P23 and 168C60 
envelope proteins, and to confirm that coreceptor pathway is not a primary 
determinant of neutralization sensitivity. We found that infection of U87-CD4- 
CXCR4 cells by pseudotyped virions containing 168C60 envelope protein was 
sensitive to neutralization by MAbs 257-D, 268-D, and 50.1 at concentrations 
comparable to those determined using 168C virus (Figure 4). Pseudotyped 
virions containing 168P23 envelope protein remained refractory to neutralization 
by all three V3-directed MAbs, regardless of the coreceptor expressed by the 
U87-CD4 cell line.
In summary, we examined the relationship between coreceptor utilization 
and sensitivity to neutralization by V3-directed MAbs. The observed dichotomy in 
the sensitivity to neutralization of PI and TCLA viruses had suggested a discrete 
difference between these viruses, and we tested one hypothesis - that PI viruses 
are refractory to neutralization as a result of their unique ability to utilize the 
CCR5 coreceptor, rather than CXCR4. We examined neutralization sensitivity of 
a well-characterized SI primary isolate under experimental conditions wherein 
the virus was forced to utilize either CCR5 or CXCR4 for infection. We showed 
that coreceptor pathway is not a direct determinant of neutralization sensitivity.
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The primary virus envelope protein remained refractory to neutralization by V3- 
directed MAbs regardless of the coreceptor pathway utilized. Similarly, 
coreceptor utilization did not affect neutralization sensitivity by soluble CD4 (34) 
or HIVIG (data not presented).
In discarding the otherwise attractive hypothesis that PI viruses escape 
neutralization through their unique ability to utilize CCR5, we are left to consider 
the as-yet undefined structural differences between the envelope protein 
complex of PI and TCLA viruses. Several studies have suggested that critical 
determinants in the envelope protein of PI viruses are less accessible than those 
of TCLA viruses and that it is this differential access that determines 
neutralization sensitivity (reviewed in 25). By contrast, our studies have 
indicated similar binding of V3-directed MAbs to PBLs infected with 
neutralization-resistant 168P or neutralization-sensitive 168C viruses (37). Thus 
the basis for the differential neutralization sensitivity of PI and TCLA viruses 
remains unresolved.
Our present studies also do not address whether changes in coreceptor 
utilization and/or neutralization sensitivity are necessarily linked as a 
consequence of adaptation. The analysis of independently-derived PI and TCLA 
viruses may allow further separation of these viral phenotypes. Subsequent 
dissection of the amino acid changes that distinguish pedigreed PI and TCLA 
envelope proteins will help to define the structural bases underlying the changes 
that accompany adaptation.
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Figure Legends
Figure 1: Coreceptor utilization by pedigreed PI and TCLA 168 viruses. U87- 
CD4 cell lines expressing CXCR4 (■) or CCR5 ( ) were used to define the ability 
of 168P and 168C viruses to utilize the respective coreceptor. CCR5 utilization 
was further tested by the addition to U87-CD4-CCR5 cells of CCR5-specific 
chemokines (RANTES, MIP-1a, and MIP-1P; R&D Systems) (□). Virus stocks 
were prepared from cell culture supernatants of PBLs (168P) or FDA/H9 cells 
(168C) and standardized to yield a submaximal number of foci of infection on 
U87-CD4-CXCR4 cells (approx 100-200 foci/96 well microplate culture). CCR5- 
specific chemokines (500 ng/ml each) were added to cells 1 hr prior to infection. 
After 2 days of incubation, cell monolayers were fixed with methanokacetone and 
immunochemically stained using HIVIG (29), anti-human ABC kit (Biomeda 
Corp), and DAB substrate. * no foci were observed.
Figure 2: Neutralization sensitivity of 168 viruses in PBL culture. Virus 
neutralization assays in PHA-stimulated PBL culture were performed as 
previously described (37). 168P (O,#) and 168C (□,■) virus stocks were 
standardized to yield submaximal extents of virus spread during the 5 day 
infection. CCR5-specific chemokines (• ,■ )  were added as described in Figure 1. 
The V3-directed MAbs are indicated. p24 antigen was determined using p24 
antigen capture ELISA (SAIC Frederick) and was normalized to infected cell 
control values (168P -190 ng/ml, 170 ng/ml with chemokines; 168C - 36 ng/ml,
33 ng/ml with chemokines).
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Figure 3: Neutralization sensitivity of 168 viruses in U87-CD4 cell lines 
expressing CCR5 or CXCR4 coreceptor. 168P (O .*) and 168C (■) viruses were 
used to infect U87-CD4 cell lines expressing CXCR4 (•.■ ) or CCR5 (O) as 
described in Figure 1. The V3-directed MAbs were incubated with virus for 1 hr 
prior to infection.
Figure 4: Neutralization sensitivity of pseudotyped virions in U87-CD4 cell lines 
expressing CCR5 or CXCR4 coreceptor. Pseudotyped virions were derived by 
cotransfection of COS-7 cells with pSVNLthyABg/ provirus and plasmid 
expressing 168P23 (O ,*) or 168C60 (■) envelope protein. Virion preparations 
were incubated with U87-CD4 cell lines expressing CXCR4 (• ,■ ) or CCR5 (O) 
as described in Figure 1; V3-directed MAbs were added as indicated. The 
number of foci was normalized to control values (60-100 foci/well using U87- 
CD4-CXCR4 cells; 10 foci/well using U87-CD4-CCR5 cells). *, no foci were 
observed.
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Abstract
Current recombinant HIV gp120 protein vaccine candidates fail to elicit 
antibodies capable of neutralizing infectivity of primary patient isolates. Here, 
novel ‘fusion-competent’ HIV vaccine immunogens are discussed that capture 
the transient envelope-CD4-coreceptor structures which arise during HIV binding 
and fusion. In a transgenic mouse immunization model, these formaldehyde- 
fixed whole cell vaccines elicited antibodies capable of neutralizing infectivity of 
23 of 24 primary HIV isolates from diverse geographic locations and genetic 
clades A-E. Development of these novel fusion-dependent immunogens may 
lead to a broadly effective HIV vaccine.
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The expanding epidemic of HIV infection threatens to engulf more than 40 
million persons worldwide by the year 2000 (1). The need for an effective HIV 
vaccine is urgent, but progress towards this goal has been slowed in part by the 
inability of any vaccine candidate to elicit antibodies capable of neutralizing 
infectivity of primary HIV isolates (Pis) from infected individuals (2). Because the 
HIV envelope protein mediates the early binding and entry steps in infection, 
many vaccine strategies have focused on this target. In 1993, two recombinant 
forms of the surface gp120 subunit of the HIV envelope protein (rgp120) were 
advanced as candidate vaccines for a large scale efficacy study sponsored by 
the National Institutes of Health (NIH). These rgp120 vaccines had been shown 
in clinical studies to be safe and to elicit antibodies capable of potently 
neutralizing related laboratory-adapted isolates of HIV (3). Progress was stalled, 
however, by findings that PI viruses, in contrast to their laboratory-adapted 
derivatives, were entirely refractory to neutralization by rgp120 vaccine sera (4). 
Although we now appreciate that laboratory-adapted isolates grown extensively 
in established T-cell lines differ in neutralization sensitivity from primary isolates 
taken from infected persons and subjected to limited growth in primary T 
lymphocytes, the basis for this difference remains unclear (5). More importantly, 
however, no HIV vaccine candidate has been shown to elicit potent and broad 
neutralization of biologically relevant primary isolates of HIV.
In contrast to antibodies elicited by rgp120 vaccines, antibodies from 
persons actively infected with HIV are able to neutralize infectivity of PI viruses,
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albeit incompletely (6). Surveys of patient sera typically report low-level 
neutralization of 30-50% of primary isolates, although breadth and titers vary.
We speculated that this ability to neutralize PI viruses might be related to the 
presentation of functioning envelope protein in active infection, as compared to 
the static, non-functioning presentation of the envelope protein in rgp120 
vaccines.
It has long been known that the oligomeric envelope protein complex 
binds the cell surface CD4 molecule (7). However, with the recent discovery of 
HIV coreceptors (8) has come a new vision of the dynamics of HIV envelope 
protein function. We now recognize that the HIV envelope protein orchestrates a 
complex series of protein-protein interactions and structural changes that 
ultimately results in fusion of the virus and cell membranes, and infection of the 
cell. Upon binding to CD4, the envelope protein undergoes conformational 
change that facilitates subsequent interaction with one of several coreceptor 
molecules (9). These 7-transmembrane domain G-protein-coupled cellular 
proteins normally function as receptors for chemokines, small proteins that 
mediate a variety of cell-cell interactions including those in inflammation. HIV 
utilizes these coreceptors as necessary components for membrane fusion. In 
general, non-syncytium-inducing (NSI)/monocytropic PI viruses use the CC 
chemokine receptor 5 (CCR5), whereas SI/T-lymphocytropic PI viruses use both 
CCR5 and the CXC chemokine receptor 4 (CXCR4). Interaction with either 
coreceptor induces further conformational change in the envelope protein and 
exposure of the hydrophobic fusion domain of the transmembrane gp41 subunit,
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which then mediates fusion of the apposed cell and virus membranes (10). On 
the basis of this dynamic model of HIV binding and entry, we undertook to 
develop HIV vaccine immunogens that explicitly incorporate these functional 
intermediate structures.
One measure of envelope protein function is the ability to mediate cell-cell 
fusion. When cells expressing envelope protein are cocultured with cells 
expressing CD4 and coreceptor, multinucleated syncytia form over the course of 
6-24 hr (Fig 1). For our vaccine studies, we asked whether this process of 
binding and fusion might be captured in progress by formaldehyde-crosslinking 
prior to extensive syncytium-formation. In these studies, the functioning envelope 
protein was derived from a T-lymphocytropic PI virus obtained from the 
Amsterdam Cohort (ACH168.10; 168P) (11). The molecularly cloned envelope 
protein, as well as the parental SI virus, utilizes both CCR5 and CXCR4 
coreceptors. COS-7 cells were transfected to express the envelope protein 
(COS-env) and subsequently cocultured with human U87 glioma cells that 
express CD4 and CCR5 coreceptor (U87-CD4-CCR5) (12). To capture 
transitional intermediates during the process of binding and fusion, cocultures 
were fixed in 0.2% formaldehyde after 5 hrs (13) when few if any multinucleate 
cells were evident (Fig 1). This inactivated whole cell preparation is the ‘fusion- 
competent’ immunogen.
In order to meaningfully test the ability of these complex immunogens to 
elicit neutralizing antibodies, it was necessary to restrict the immune response to 
viral and virus-induced epitopes. Otherwise, antibodies to CD4 and CCR5 would
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be generated that would themselves block infectivity. Therefore, it was essential 
to use an animal model that was immunologically tolerant to the human (hu) CD4 
and CCR5 components of the vaccine, as would also be the case in human 
immunization. Thus, immunogenicity studies were performed using transgenic 
mice that express hu CD4 and hu CCR5 coreceptor.
These transgenic mice were originally developed as a potential small 
animal model for HIV infection (14). Expression of hu CD4 is regulated by a 
murine enhancer linked to a human CD4 minigene and is active in thymocytes, T 
helper lymphocytes, and monocyte lineage cells. Expression of the hu CCR5 
cDNA is under the control of a murine CD4
expression cassette and is active in thymocytes and T helper lymphocytes. 
Although post-entry blocks to HIV replication have to date limited the utility of this 
transgenic model in infectivity studies, these animals were expected to be 
immunologically tolerant to the expressed human transgenes. Mice expressing 
all three relevant markers (hu CD4, hu CCR5, and mouse CD4) were used in the 
immunogenicity studies reported here (15). Formaldehyde-fixed immunogens 
were formulated with Ribi Adjuvant and mice were immunized subcutaneously at 
3 week intervals (16).
In pilot studies, mice were immunized with either ‘fusion-competent’ 
immunogen or with cell controls (U87-CD4-CCR5 cells, alone or cocultured with 
mock-transfected COS cells). Sensitivity of the homologous 168P virus to 
neutralization by vaccine sera was determined using U87-CD4 cells expressing 
either CCR5 or CXCR4 coreceptor (17). No inhibition of infectivity was observed
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in sera from mice immunized with cell controls, suggesting that the transgenic 
mice were in fact tolerant to hu CD4 and CCR5 and that other adventitious 
cellular reactivities did not interfere with the virus infectivity assay (Fig 2A).
More importantly, however, sera from mice immunized with ‘fusion- 
competent’ immunogens were able to neutralize the homologous 168P PI virus. 
Additional studies demonstrated that this neutralization activity was antibody- 
mediated and could be adsorbed to, and subsequently eluted from, a solid 
support containing Protein-A and Protein-G (18). In our experience, 
neutralization of this PI virus by vaccine antiserum was unprecedented.
Furthermore, neutralization of the 168P virus by ‘fusion-competent’ serum 
was observed regardless of the coreceptor used in the U87-CD4 cell infection 
assay (Fig 2A). Several reports have demonstrated that in general neutralization 
sensitivity is independent of specific coreceptor use (19). The fact that 
neutralization is observed in this study using CXCR4, a coreceptor to which the 
animal had not been exposed, argues that neutralization does not directly target 
the CCR5 component of the vaccine.
To explore the role of fusion-dependent determinants in the induction of 
PI virus neutralization, we expanded our studies to include ‘fusion-incompetent’ 
immunogens - cocultures that do not undergo cell-cell fusion. ‘Fusion- 
incompetent’ immunogens tested include: COS-env cocultured with U87 cells (no 
CD4 or CCR5 coreceptor), COS-env cocultured with U87-CD4 cells, and COS- 
env cells to which soluble CD4 (sCD4) was complexed (20). These immunogens 
were fixed with formaldehyde and harvested (12, 13). An additional ‘fusion-
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incompetent’ immunogen comprised COS-env and U87-CD4-CCR5 cells that 
were separately fixed with formaldehyde prior to mixing during the formulation of 
the vaccine. Results from neutralization studies of ‘fusion-competent’ and - 
‘fusion-incompetent’ vaccine sera are summarized in Fig 2B. .
In marked contrast to ‘fusion-competent’ immunogens, all ‘fusion- 
incompetent’ immunogens were unable to elicit significant neutralization of the 
homologous PI virus. These results are consistent with the well-documented 
failure of rgp120 vaccines to elicit PI virus neutralization. The striking distinction 
in neutralization by ‘fusion-competent’ and ‘fusion-incompetent’ vaccine sera was 
also observed in assays utilizing human primary blood lymphocytes (PBLs) (Fig 
3).
As with conventional rgp120 vaccines, ‘fusion-incompetent’ vaccines were 
able to elicit neutralization of a related laboratory-adapted isolate, in this case the 
T-cell line adapted derivative of 168P, 168C (21) (Fig 4). Neutralization titers of 
the TCLA 168C virus were comparable among ‘fusion-competent’ or ‘fusion- 
incompetent’ vaccine sera, suggesting a similar degree of inherent 
immunogenicity among the vaccines.
The failure of ‘fusion-incompetent’ vaccines to elicit PI virus neutralization 
in the transgenic mouse model highlights the specificity of the neutralization 
elicited by ‘fusion-competent’ vaccines (22). Furthermore, the consistent failure 
of ‘fusion-incompetent’ vaccine sera to inhibit PI virus infectivity argues strongly 
that the immune response is not directed to adventitious human cellular targets, 
such as those that confounded early studies of inactivated SIV vaccines (23).
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Rather, we suggest that ‘fusion-competent’ immunogens present unique fusion- 
dependent determinants that mediate neutralization of PI viruses.
Although the potent neutralization demonstrated against the homologous 
PI virus is unprecedented in HIV vaccine experience, it is understood that the 
‘homologous’ virus will never be encountered in nature. HIV is an enormously 
variable virus that exists as a swarm of related, rapidly-evolving genotypes that 
cluster into phylogenetically-defined clades (24). Thus, a critical issue in HIV 
vaccine development centers on the ability of vaccine antisera to neutralize a 
broad range of diverse PI viruses.
To determine the breadth of PI virus neutralization elicited by ‘fusion- 
competent’ immunogens, we examined the sensitivity of a panel of 
representative PI viruses from five prevalent and geographically-diverse genetic 
clades (25). As depicted in Fig 5, ‘fusion-competent’ sera elicited by a functioning 
clade B envelope protein were able to neutralize 23 of 24 PI viruses tested - 
monocytropic/NSI and T-lymphocytropic/SI viruses from North America/Europe 
(clade B), Africa (clades A and D), Thailand (clades B and E), and India (clade 
C). Despite the sequence diversity among these isolates, most were similarly 
sensitive to neutralization by ‘fusion-competent’ vaccine sera. One clade A 
isolate 92RW008 failed to attain >50% neutralization; this exception to the 
otherwise broad pattern of neutralization further argues that ‘fusion-competent’ 
immunogens target primarily viral, rather than cellular, determinants. ‘Fusion- 
incompetent’ sera were uniformly unable to neutralize these heterologous PI 
viruses, in keeping with the historic failure of rgp120 immunogens. The broad
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and uniform neutralization of diverse PI viruses suggests that the critical 
determinants presented by fusion-competent’ immunogens are highly 
conserved, and may be intimately tied to the basic functioning of the envelope 
protein in binding and fusion.
We then sought to define the molecular target for PI virus neutralization 
by ‘fusion-competent’ vaccines. We had shown that the elicitation of PI virus- 
neutralizing antibodies required as immunogen a functional envelope-CD4-CCR5 
interaction. Nonetheless, these neutralizing antibodies might recognize native, 
non-functioning envelope protein as antigen. A similar instance has been 
reported for monoclonal antibody (mAb) 17b (26) which targets a CD4-induced 
epitope on the gp120-CD4 complex but which also binds isolated gp120. 
Alternatively, another gp120-CD4 specific mAb CG10 (27) does not recognize 
isolated gp120 or CD4. Thus, we tested whether neutralizing antibodies could be 
removed from ‘fusion-competent’ vaccine sera on incubation with envelope 
protein complex expressed on the surface of transfected COS cells. 
Formaldehyde-fixed COS cells expressing 168P envelope protein were 
incubated with ‘fusion-competent’ serum and the recovered serum was then 
tested for PI virus neutralization (28). Neutralization activity in ‘fusion-competent’ 
vaccine serum was removed by incubation with envelope-expressing cells, but 
only minimally reduced by incubation with COS cell controls (Fig 6). Although the 
static form of the envelope protein does not function as an effective immunogen, 
we found that the critical fusion-dependent epitopes are sufficiently represented 
on the static protein to allow binding. These data argue that PI virus neutralizing
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antibodies target, at least in part, the HIV envelope protein. Studies in progress 
will define the role of specific envelope protein sequences in binding, as well as 
the possible contribution of virus-induced CD4 or CCR5 determinants. 
Importantly, these data also provide independent support to our argument that 
neutralizing antibodies do not target adventitious cellular targets; any such . 
targets would be equally recognized (or not recognized) on control COS cells.
Further delineation of the critical PI virus neutralizing determinant(s) 
captured by ‘fusion-competent’ immunogens will be facilitated by the 
development of PI virus neutralizing mAbs to ‘fusion-competent’ immunogens. 
Based on the requirement for interaction with coreceptor, we speculate that 
neutralization may target a late event in virus binding and entry. Upon binding to 
coreceptor, the envelope protein must mediate fusion of the viral and cell 
membranes. Cryptic but highly conserved determinants may be exposed during 
this process. One possible target for neutralization might involve the triple­
stranded coiled-coil structure that mediates membrane fusion and is highly 
conserved among Orthomyxoviridae (Influenza), Filoviridae (Ebola), and 
Retroviridae (HIV) as well as in fusion of cellular membranes (29). The fusion- 
active structure of the HIV envelope protein is believed to form subsequent to 
CD4 and coreceptor binding by the collapse of two helical coils within each gp41 
monomer to form the trimeric coiled-coil core. This structure is thought to drive 
membrane insertion of the hydrophobic fusion domain of gp41 and to initiate 
membrane fusion. Synthetic peptides that comprise either of the gp41 helical 
coils are able to bind the cognate helical region and broadly inhibit viral infectivity
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(30). We speculate that broadly-neutralizing antibodies to ‘fusion-competent’ 
immunogens may likewise target structures involved in the activation of fusion.
The potency and breadth of neutralization by ‘fusion-competent’ 
immunogens appears to surpass that observed in sera from infected individuals. 
Perhaps formaldehyde-fixation traps critical fusion-dependent structures that are 
only transiently presented during active infection. It remains to be determined 
whether ‘fusion-competent’ immunogens target the same neutralizing 
determinants as active infection.
The ability of antibodies induced by ‘fusion-competent’ immunogens to 
neutralize a broad range of PI viruses necessitates a shift in our thinking of HIV 
vaccines. Whereas previous discussions regarding the possible number of HIV 
serotypes were moot in the absence of any vaccine-induced neutralization, it had 
been widely accepted that multiple envelope protein immunogens might be 
needed to span the range of HIV sequence diversity. We now show that an 
appropriately-presented clade B envelope protein can elicit potent neutralization 
against most PI viruses, from multiple HIV clades. We show that not only is PI 
virus neutralization achievable, we suggest that broad vaccine protection may 
not require an unlimited number HIV serotypes.
Although the immunological basis for HIV vaccine efficacy is presently 
unknown and controversial, there is ample reason to believe that pre-existing 
neutralizing antibody may offer protection against infection and/or disease. 
Passively administered neutralizing antibodies can exert potent antiviral effects 
in several experimental models of HIV infection, as manifested by complete or
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partial protection (31). Antibody-mediated protection is, of course, well-accepted 
in other viral infections and vaccines (32). With the ability to elicit potent HIV 
neutralization will come the opportunity to determine the role of pre-existing 
neutralizing antibody in HIV prophylaxis. Concerns regarding the diversity of HIV 
populations are lessened by the breadth of neutralization elicited by ‘fusion- 
competent’ immunogens. Still, one may raise the concern that antibodies in HIV- 
infected persons do not protect against disease progression. Whether the 
ultimate disease course is modified by the ongoing antibody response is difficult 
to assess. In any case, an established chronic infection presents special 
challenges in terms of host competence and virus load and diversity, challenges 
that are distinct from those envisioned in prophylactic immunization. The effect of 
pre-existing antibodies in exposure to a minimal infectious dose of virus in an 
immunocompetent host remains to be determined in preclinical and clinical 
studies.
We recognize that in its current form an inactivated whole cell ‘fusion- 
competent’ vaccine is not practical for clinical development. Nonetheless, ‘fusion- 
competent’ formulations that incorporate critical fusion-dependent determinants 
of PI virus neutralization can be envisioned. For example, recombinant viral 
vectors that respectively express envelope and CD4 with coreceptor could be 
coadministered to drive critical fusion events in vivo. Alternatively, purified fusion- 
active complexes could be developed as an inactivated subunit vaccine. This 
novel concept of ‘fusion-competent’ immunogens may also be applicable to other
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enveloped viruses where protection has been difficult to generate other than by 
live attenuated virus immunization.
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Figure 1. Cell-cell fusion in cocultures of COS-env and U87-CD4-CCR5 cells 
(12). Both fields are at 200x magnification.
Figure 2. Neutralization of the homologous 168P PI virus by ‘fusion-competent’ 
and fusion-incompetent’ vaccine sera. (A) Transgenic mice (hu CD4+, hu 
CCR5+, mouse CD4+) in Studies 1-3 were immunized with ‘fusion-competent’ 
immunogen (COS-env with U87-CD4-CCR5) (■, □ ; n = 3 mice) or with cell 
controls (U87-CD4-CCR5 cells alone or cocultured with mock-transfected COS 
cells) ( • ,  D; n = 3 mice). Unimmunized mice were also used (A , A; n = 2 mice). 
Sera were tested for neutralization of 168P using U87-CD4 cells expressing 
either CXCR4 (■,•,▲ ) or CCR5 (0 ,0 , A). Data represent averages of 3-6 
neutralization assays using serum obtained 2 weeks following second and third 
immunization. (B) Transgenic mice in Study 4 were immunized with ‘fusion- 
competent’ immunogen (■, n = 4), ‘fusion-incompetent’ immunogens (COS-env 
with U87 cells, n = 4; COS-env with U87-CD4 cells, n = 3; COS-env with 
sCD4, on = 2; COS-env with U87-CD4-CCR5 cells, each fixed separately prior to 
mixing for immunization, n = 2). Mock-transfected cell controls (O; n = 2) and 
unimmunized mice (A; n = 2) were also used. Neutralization was independent of 
specific coreceptor use (Fig 1 A) and data here represent averages of 3-6 
neutralization assays in U87-CD4-CXCR4 or -CCR5 cells. In some cases 
individual animals were pooled to conserve serum.
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Figure 3. Neutralization of the homologous 168P PI virus in human PBL culture 
Lymphocytes were isolated, stimulated with phytohemagglutinin, and grown in 
the presence of interleukin-2; neutralization was determined as.described (17). 
HIV p24 antigen was determined after 5 days of culture by ELISA (Coulter 
Corporation). Vaccine groups are as defined in Fig 2B, and sera from individual 
animals were pooled for this assay.
Figure 4. Neutralization of TCLA 168C virus by ‘fusion-incompetent’ vaccine 
sera. Neutralization sensitivity of the 168P PI virus and its TCLA derivative 168C 
were tested in U87-CD4-CXCR4 cells. Vaccine groups and symbols are as 
defined in Fig 2B; sera from individual animals were pooled for this assay.
Figure 5. Neutralization of diverse PI viruses from clades A-E. Primary isolates 
were expanded in human PBLs and neutralization was determined in permissive 
U87-CD4-CCR5 (or -CXCR4) cells. Viral biotype is indicated if known. Vaccine 
groups and symbols are as defined in Fig 2B; sera from individual animals were 
pooled for this assay.
Figure 6. Adsorption of PI virus neutralization activity by formaldehyde-fixed 
COS-env cells. ‘Fusion-competent’ vaccine serum (■) was repeatedly incubated 
with formaldehyde-fixed COS-env ( ) or control COS (□) cells and tested for
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residual neutralization of 168P using U87-CD4-CXCR4 cells (27). Prebleed 
serum was similarly adsorbed ( • ,  .3 . respectively).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
80
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
81
F o c i  ( %  c o n t r o l )
H(O
3
ocm
CD
in
CD-r 
C
3
Q.
O -
c
o
3
o
©
o
F o c i  ( %  c o n t r o l )
oo
H
(Q
3
ocm
CD
CD O  
C o  -
3  ^ ;
Q.
E"
o3
o
U3
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Fig. 2
0.1 0.01 0.001 
Tg mouse serum dilution
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Foci (% control) 83
H
(Q
3
ocCO
CD
CO
CD
C
3  
Q.
C*rt-
o ’
3
O
<X>
00
“O
“Oo  ■
O  -
Foci (% control)
(Q
3
oc10
CD
CO
CD
c
3
c  ^
o3
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Fig. 4
00
CLADE B 
CLADE A
M
O
*
M
O
-
rXV*-<r
/
 
NS! 
J 92US657
/ 
NSl 
f
 92U
S660
I 
S1
■* 
92RW
023
1 
I
M
 
M
O
 
M
B
 
ME
»
< 
HO
 
KCO 
M
DO
0 
M
O 
M
O
 
M
O
M
O
'
•'V
'"
N
O
-
°->
y
kv
/
 
NSl 
92TH
014
■* 
SI
89.6
/
 
NSl 
92UG
031
M
 
tOO 
K
lfl 
KtS
o 
m
o
 
n
o
 
m
IB
0
 
M
O 
M
O
 
MO
H
O
­
n
»
1
320NSI
* 
320S1
/
NSl
92U
G
037
M
 
M
O 
H
O
 
K
B
tB
 
t0 
M
O 
K
10 
H
A
S
 
,
- 
’ 
“i 
"i™
 
“
-~
H
0 
M
O
 
K
O
 
m
/
*
M
O •
•
y
™
K
U
-
js
h
iv
89.6p 
. -
 
■ 
■
M
 •
SI
168P
1 
■■ 
t 
-
 
■■■ 
r
 
"■
M
NSl
92R
W
008
CLADE C 
CLADE D 
CLADE E
93IN
101
92U
G
035
too
93IN
999
to
to
too
tca>
too
92UG
021
w
too
KXD
92TH023
<• 
V
A.1 
>
NSl 
92TH
024
too
92U
G
024
93TH051
to
KSUO
93IN
905
w
KB
92U
G
046
to10
M
S
M
O
KB
93IN
904
toto
M
O
H
O
H
O
'
93TH053
to
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
85
F i g .  6
c  
oo
£
o
o
00
10
0.0010.1 0.01
Tg mouse serum dilution
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Chapter 4
Discussion
The HIV envelope protein initiates a series of complex protein-protein 
interactions that ultimately lead to the fusion of the virus and cell membranes. 
This process of envelope-mediated fusion has lead to the vision of a protein that 
undergoes a series of complex conformational changes that expose potential 
neutralizing epitopes that are conserved throughout the different clades of HIV. 
We have developed a vaccine strategy that incorporates these fusion-dependent 
epitopes of the functioning envelope into the immunogen, in contrast to the 
current vaccine candidates which are composed of a static, nonfunctioning 
envelope. We propose that it is the incorporation of the functioning envelope 
interacting with CD4 and coreceptor that has made this vaccine strategy 
successful in eliciting antibodies capable of neutralizing Pis of HIV in vitro.
There are numerous studies that will stem from this project. First and
foremost, spleens from the ‘fusion-compenent’ vaccinated mice will be harvested
to produce hybridomas for monoclonal antibody production. These monoclonal
antibodies will be essential for the elucidation of the epitope(s) responsible for
the production of neutralizing antibodies within this vaccine. Interestingly, it has
recently been shown that a peptide (DP-178) corresponding to the helical regions
of the gp41 core (the coiled-coiled core that consists of the leucine zipper motif)
is a potent inhibitor of HIV infection (1-4). This peptide is able to bind to the
envelope protein and inhibit conformational changes that are necessary for
envelope-mediated fusion (4-6). It was found that this peptide is
86
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only able to bind to the envelope complex and inhibit fusion after it interacts with 
the cellular receptors, suggesting the coiled-coil domain of gp41 may become 
accessible during the fusion process (7). It could be hypothesized that this 
region is transiently accessible during binding and entry events and could be a 
potential epitope for neutralization. Future studies include evaluation of our . 
vaccine sera to determine if the neutralizing antibodies target this region of gp41, 
as well as define other epitopes present in both gp41 and/or gp120 responsible 
for eliciting neutralizing antibodies of PI viruses.
It is recognized that the current form of the inactivated whole cell ‘fusion- 
competent’ vaccine is not practical for clinical development. Therefore, vaccine 
strategies incorporating the critical fusion-dependent determinants of 
neutralization will be developed. One approach being taken is to utilize 
recombinant viral vectors (e.g. vaccinia) that would respectively express 
envelope and CD4 with coreceptor. These recombinant vectors would then be 
coadministered to drive the fusion events in vivo. An additional approach to be 
pursued is to purify the fusion-active complexes comprised of envelope, CD4, 
and coreceptor, and incorporate these complexes into an inactivated subunit 
vaccine. The development of these vaccine strategies to elicit neutralizing 
antibodies to PI viruses will hopefully lead to a pratical formulation of the ‘fusion- 
competent’ vaccine for application in humans.
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Part 2
Chapter 5 
General Introduction
Feline immunodeficiency virus (FIV) is a lentivirus that causes a natural 
immunosuppressive disease in cats that is very similar to AIDS in humans (1-4). 
FIV is similar to HIV-1 not only in disease progression, but also in sensitivities to 
many of the antiviral drugs used in AIDS chemotherapy and in its ability to 
develop resistance to these drugs. In the past, the FIV model system had been 
developed to study the phenomenon of drug resistance (5-7). However, it has 
now been expanded to evaluate the mutation frequency of the virus and how it is 
affected by antiviral therapy.
Antiviral agents usually target a viral component that is required for 
replication, such as a receptor needed for entry or an enzyme that is essential to 
the replication of the viral genome. One such target is the viral RNA-directed 
DNA polymerase, or reverse transcriptase (RT) of retroviruses. This enzyme is 
required for the synthesis of a double-stranded DNA copy of the single-stranded 
RNA viral genome. A number of reverse transcriptase inhibitors have been 
approved and used for AIDS chemotherapy, including 3’-azido-3’-deoxythymidine 
(AZT), 2’,3’-dideoxycytidine (ddC), 2’,3'-dideoxyinosine (ddl), and 2’-deoxy-3’- 
thiacytidine (3TC).
The RT of FIV has been shown to be similar to HIV-1 RT in physical 
properties, catalytic activities, and sensitivities to several important antiviral
89
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nucleosides (9-12). Both of these enzymes have similar Mg** requirements and 
similar template specificities. The sensitivities to various RT inhibitors are also 
very comparable. The competitive inhibitors 2 \3 ’-dideoxythymidine 5’- 
triphosphate (ddTTP), 2 \3 ’-dideoxycytidine 5’-triphosphate (ddCTP), 3’-fluoro-3’- 
deoxthymidine 5’-triphosphate (3-F-dTTP), 2’,3,-dideoxy-2’,3’- 
didehydrothymidine 5’-triphosphate (d4TTP), and 3’-amino-3’-deoxythymidine 
5’-triphosphate (3’-NH2-dTTP) were determined to have similar inhibition 
constants for both HIV-1 and FIV RT. This also held true for phosphonoformate 
(PFA) and phosphonoacetate (PAA), two noncompetitive inhibitors of RT (9,11). 
In addition, it has been found that the FIV RT has a low fidelilty, similar to that 
described of HIV-1 RT (Garvey et al., unpublished observations). These 
features have made the FIV model highly relevant to HIV.
The RT inhibitor AZT is a nucleoside analogue that has been found to 
have potent antiviral activity against HIV-1, and was the first nucleoside analogue 
to be approved for use in AIDS chemotherapy (12). AZT requires activation by 
cellular enzymes to its active form, AZT triphosphate (AZl IP). This activated 
form is a dTTP analogue and competes with the natural substrate in the cell, 
dTTP, for incorporation into the growing chain of DNA by RT. Once AZT has 
been incorporated, the 3-azido group blocks the formation of the 3’,5’- 
phosphodiester bond that is necessary for chain elongation, hence, DNA 
synthesis is terminated. (12). This drug is widely used for treatment of HIV 
infection.
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The following study utilizes the FIV system to evaluate the mutation 
frequency of this retrovirus. The high mutation rate of HIV is believed to be a 
critical factor in the ability of the virus to evade the immune system (13). It also 
may contribute to the emergence of drug-resistant variants seen in patients 
undergoing antiviral chemotherapy (13-15). Therefore, it is important to evaluate 
the effect antiviral drugs have on the mutation frequency of the virus during 
chemotherapy.
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Summary
We have developed a host range system to measure the mutation frequency of 
feline immunodeficiency virus (FIV), the feline homologue of human 
immunodeficiency virus type 1 (HIV-1). When wild-type FIV was grown in the 
presence of a known mutagen, 5-bromo-2’-deoxyuridine (BUdR), a dose- 
dependent increase of host range mutants was detected. Using this system, we 
have evaluated the effects of antiviral drugs upon the mutation frequency of FIV. 
Subinhibitory concentrations of 3’-azido-3’-deoxythymidine (AZT), the most 
common antiviral drug used in AIDS chemotherapy, increased the mutation 
frequency of FIV in a dose-dependent manner. Two other antivirals, 2’,3’- 
dideoxyinosine (ddl) and 2’,3’-dideoxycytidine (ddC) did not show this effect.
Key words: Antiviral drugs-Feline immunodeficiency virus-Lentivirus mutation 
frequency.
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Introduction
The high mutation frequency of human immunodeficiency virus type 1 (HIV-1) (1- 
3) is a major barrier to development of vaccines and chemotherapy and may also 
be important in the pathogenesis of the acquired immune deficiency syndrome 
(AIDS) (4). The high misincorporation rate of HIV-1 reverse transcriptase (RT), 
estimated to be 2.5-5 x 1CT4 with either DNA or RNA templates, is believed to 
play a major role in this. RT infidelity would result in five to ten errors each time 
the genome is replicated (2,3), although the actual mutation rates may be 
substantially lower than would be predicted by fidelity of RT in vitro (5). This high 
variability is believed to be a critical factor in the ability of the virus to evade the 
immune system, and it is a substantial limitation to development of a vaccine (4). 
The high mutation frequency of HIV-1 may also contribute to the emergence of 
drug-resistant variants, a serious problem faced in the treatment of AIDS 
patients (4,6,7). High variability is also seen from the genotypic differences 
between HIV-1 isolates obtained from AIDS patients versus the isolates obtained 
early after infection. It has been suggested that the accumulation of mutations 
affecting tropism, replication rates, and so on may contribute to the pathogenesis 
of AIDS (4,8,9). Since the high mutation frequency of the virus appears to be 
important in terms of pathogenesis and therapy, the effects of antiviral drugs 
upon mutation frequency need to be considered. Therefore, we have developed 
a system to evaluate the effects of antiviral drugs on mutation frequency of a 
lentivirus, and we report here that the most widely used anti-HIV-1 drug, 3-azido-
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3’-deoxythymidine (AZT), increases the mutation frequency of feline 
immunodeficiency virus (FIV).
Although the high error rate of HIV-1 RT is well documented, assessment 
of the mutation rate at the level of virus replication has been difficult. Point 
mutation rates of a murine retrovirus, murine leukemia virus, have been 
determined (10), as have the mutation rates of the spleen necrosis virus 
containing a reporter gene (11). However, no data are available on mutation 
rates or frequencies using endogenous genes of a replicating virus, and no data 
are available for a lentivirus.
Our main interest in lentivirus mutation frequencies is in the rate of 
emergence of drug-resistant variants. We have previously developed a model 
system using FIV for studies of resistance to AZT and other antiviral drugs (12- 
14). With this system, we reported the first in vitro selected AZT-resistant 
mutants (12), which are phenotypically similar to the AZT-resistant clinical 
isolates of HIV-1 reported by Larder et al. (15,16). FIV is a lentivirus that causes 
an immune deficiency in domestic cats that is clinically similar to human AIDS 
(17-20), and this immunosuppressive disease can be induced experimentally in 
specific-pathogen-free cats(21,22). We have shown that the purified FIV RT is 
similar to the HIV-1 RT in physical properties, catalytic activities, and sensitivities 
to several important antiviral nucleotides (23-26). The RT of FIV also has low 
fidelity, similar to that of HIV-1 (Garvey et al., unpublished observations).
These features make FIV an attractive model to study mutation frequency 
and how it is affected by antiviral drugs or by mutations conferring drug-
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resistance. The FIV model is also highly relevant to HIV. For these studies, we 
developed a host-range system that allows measurement of mutation 
frequencies in a manner analogous to classic genetic studies with bacteriophage 
systems (27). Using this system we can evaluate the effects of antiviral drugs on 
the mutation frequency of a lentivirus. We have presented a preliminary report 
that the most widely used anti-HIV-1 drug, AZT, increases the mutation 
frequency of FIV (28). We report here the details of the FIV host-range system 
and the effects of antiviral nucleosides on the mutation frequency of FIV.
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Chemicals
5-bromo-2’-deoxyuridine (BUdR) and 2’,3’-dideoxycytidine (ddC) were 
purchased form Sigma Chemicals Co. (St. Louis, MO, U.S.A.). AZT was 
provided by Phillip A. Furman of Burroughs Wellcome Co. (Research Triangle 
Park, NC, U.S.A.). 2',3’-Dideoxyinosine (ddl) was provided by the 
Developmental Therapeutics Branch, Division of AIDS, National Institute of 
Allergy and Infectious Diseases.
Virus and Ceils
The virus strains used in this study were FIV Petaluma (17,19) and FIV 
34TF10, a molecular clone derived from the Petaluma strain (29). Virus was 
grown and maintained in Crandell feline kidney (CrFK) cells, which were 
obtained from American Type Culture Collection (ATCC) and were cultured 
under condition previously described (26). An FIV-resistant variant of CrFK cells, 
CrFK-13, is described in Results. When cells reached confluency, they were 
passaged by trypsinization, diluted approximately 100-fold, and reseeded in 25- 
cm2 flasks. A single passage includes the period between trypsinization, dilution, 
and reseeding the cells, until they become confluent and are ready for 
trypsinization again. Cells were passaged approximately once a week. They 
were routinely tested with a Gen Probe Mycoplasma detection kit (Gen Prob
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Inc., San Diego, CA, U.S.A.) and were found to be free of any Mycoplasma 
contamination.
Focal Infectivity Assay
Infectious FIV was quantified by the focal infectivity assay (FIA) as 
previously described (12). Briefly, uninfected CrFK cells were infected with ~20- 
80 focus forming units of FIV. After 5 days, media were removed, and the cells 
were fixed with methanol. Infectious foci were detected by reacting with 
polyclonal antiserum obtained from FIV-infected, specific-pathogen-free cats 
(generously provided by N.C. Pedersen, School of Veterinary Medicine,
University of California, CA, U.S.A.) and then reacted with peroxidase- 
conjugated anti-cat immunoglobulin (Organon Teknika). The peroxidase stain 
was developed with H2O2 and amino-ethyl-carbazole. Infectious foci appeared as 
red cells against a background of uninfected (unstained) cells. Plaque 
purification of virus from a single foci was performed as previously described 
(13).
Determination of Mutation Frequencies
To determine mutation frequencies, cell-free virus was differentially plated 
on CrFK-13 (FIV-restrictive) and CrFK (FIV-permissive) cells. For these 
experiments, virus grown in the absence or presence of a mutagen or inhibitor 
was differentially plated on CrFK-13 cells and FIV-permissive CrFK cells. Before 
infection, cells were pretreated with 8 pg/ml diethylaminoethyl dextran for 20 min
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to facilitate adsorption of the virus. The values reported represent the number of 
foci formed on CrFK-13 cells divided by the number of foci formed on FIV- 
permissive CrFK cells, as determined by FIA.
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RESULTS 
Development of the Host-Range System
The system we developed uses a strain of Crandell feline kidney (CrFK) 
cells that is resistant to infection by wild-type FIV Petaluma or the molecular 
clone, FIV 34TF10. As described herein, these cells are used to measure the 
proportion of host-range mutant in a population of virus. The FIV-resistant cells 
were isolated after we observed that with prolonged passage of FIV-permissive 
CrFK cells, we obtained cells that were highly restrictive to FIV infection. Wild- 
type FIV Petaluma infected these restrictive cells ~1,000 times less efficiently 
than permissive CrFK cells, as determined by FIA. As shown in Fig. 1, the 
susceptibility of CrFK cells to infection with FIV decreased dramatically as a 
function of passage number. We are not certain of the reason for the change in 
the cells, but it is presumably due to different growth conditions. ATCC had 
grown the CrFK cells in minimum essential medium (Delbecco’s MEM) 
supplemented with 10% horse serum, which is different from the medium (L & M 
medium supplemented with 10% fetal bovine serum) (26) that is optimal for FIV 
replication.
Because the population of FIV-restrictive CrFK cells was expected to be a 
heterogeneous mixture, we isolated 19 single-cell clones from this population.
The susceptibilities of these clones to FIV infection are shown in Table 1.
Several of the clones were highly resistant to FIV, whereas others, such as 
CrFK-3, were less restrictive, confirming that the original population was a 
heterogeneous mixture. We chose one of the clonal isolates, CrFK-13, as a
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highly restrictive host cell for further characterization. This choice was made 
based upon the ability to detect a few (potentially mutant) foci of FIV with these 
cells.
From these early studies, it was determined that wild-type FIV Petaluma 
infected CrFK-13 cells, 1.4±0.4 x 10‘3, as efficiently as permissive CrFK cells. 
FIV-permissive CrFK cells are CrFK cells that have been passaged four or fewer 
times after they were obtained from ATCC. Experiments were performed to 
determine whether the occasional foci observed upon infection of CrFK-13 by 
FIV were host-range mutants that were present in the swarm population of the 
virus, rather than simply wild-type virus able to form foci owing to leakiness. We 
plaque-purified several potential mutants by isolating single foci of FIV Petaluma 
on CrFK-13 cells. The resulting host-range (HR) mutants remained infectious to 
the FIV-permissive CrFK cells and also infected CrFK-13 cells with much higher 
efficiency that the potential wild-type FIV (Table 2).
In order to ascertain whether these viruses are truly mutants, we 
assessed their phenotypic stability by passing one of the HR mutants, HR-3, 
back into the FIV-permissive CrFK cells. This was done to test the possibility 
that HR mutants were the result of a biochemical adaptation rather than a stable 
phenotype. When HR-3 was passaged back into the FIV-permissive cells, 
progeny virus retained the ability to infect CrFK-13 cells 100 fold more efficiently 
that wild-type FIV (data not shown). This finding confirmed the phenotypic 
stability of HR-3. These data suggest that the CrFK/CrFK-13 HR system could 
be useful for studies to evaluate the mutation frequency of FIV.
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With this assay, HR mutants are detectable in a normal population at a 
frequency of 0.14%. However, the actual mutation frequency is somewhat 
higher when corrected for efficiency of plating of HR mutants on CrFK-13 cells 
(Table 2). Based upon the six HR mutants we have analyzed, the average 
plating efficiencies for HR mutants range from 2.7-18%. This efficiency results in 
an actual mutation frequency somewhere between 0.8 and 5.6%. It is apparent 
that these variants represent a substantial fraction of the swarm population, but 
are at a significant disadvantage relative to wild-type FIV.
To test this system, we examine the effects of a known mutagen, BUdR 
(30), to determine whether it increases the frequency of HR mutant in a 
population. As shown in Fig. 2A, passage of wild-type FIV Petaluma in the 
presence of BUdR increased the mutation frequency in a dose-dependent 
manner, up to a level where cytotoxicity was observed (>0.7-1.0 jiM). This 
finding confirms that our system can detect an increase in the mutation 
frequency due to replication of the virus in the presence of a known mutagen.
The maximum increase in mutation frequency that we observed with BUdR is 
only 2.5- to three-fold. We believe that the extremely high basal mutation rate of 
FIV limits the extent of mutagenesis and that higher mutation rates would result 
in too many lethal mutations. We believe that the apparent leveling off of the 
mutation frequency seen with higher concentrations of BUdR is not due to an 
actual leveling off of the mutation frequency, but rather to a limitation in the 
sensitivity of the system when the inhibition of virus replication results in titers too 
low for accurate scoring of mutants.
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The experiments with BUdR was also performed with FIV obtained from 
the molecular clone FIV 34TF10, which represents a more homogenous 
population than the swarm population of FIV Petaluma. The mutation frequency 
of FIV 34TF10 also increased in the presence of BUdR. This result indicates 
that replication in the presence of the mutagen increased the mutation frequency 
of the virus regardless of the degree of heterogeneity of the starting population.
Effects of Antiviral Drugs on the Mutation 
Frequency of FIV
With the confirmation that our HR system is able to detect an increase in the 
mutation frequency due to the presence of a mutagen, we evaluated the effects 
of antiviral drugs upon the mutation frequency of FIV. As shown in Fig. 2B, when 
wild-type FIV Petaluma replicated in the presence of AZT, a dose-dependent 
increase of the mutation frequency was detected. Similar results were obtained 
in experiments with the molecular clone FIV 34TF10. We also evaluated two 
other antiviral nucleosides approved for AIDS chemotherapy. Replication of 
wild-type FIV Petaluma in the presence of ddl and ddC resulted in little or no 
detectable increase in the mutation frequency (fig 2C and 2D, respectively).
DISCUSSION
AZT is negative in the Ames test, only weakly mutagenic in assays with cultured 
mammalian cells, and weakly carcinogenic in rodents (31). However, the 
mutagenicity of AZT to FIV cannot be considered weak; AZT enhances the
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mutation frequency of FIV by nearly as much as BUdR, a well-characterized 
mutagen. This ability of AZT to enhance the mutation frequency of a lentivirus 
may have important implications for AIDS chemotherapy, but it is not clear 
whether this enhanced mutagenesis will be beneficial or detrimental. If AZT 
produces an increased frequency of lethal mutations among the population of 
virus escaping drug, it may contribute to antiviral activity. However, it is likely 
that an enhanced mutation rate will also contribute to mutations involved in 
antigenic variation, evasion of the immune system, and changes in cell tropism.
If the rate of pathogenesis is in fact dependent upon accumulation of multiple 
mutations, then AZT therapy may alter the rate of pathogenesis.
The genetic system we have developed quantitates the proportion of virus 
with a particular phenotype, in this case the number of HR mutants present 
within a population of viable virus. The baseline frequencies we report are not 
mutation rates, but rather the proportion of mutants in an equilibrium population. 
The mutation frequency of a retrovirus is dependent upon forward mutation rate, 
reverse mutation rate, replication rate, and number of replication cycles (32. 33). 
AZT lowers the replication rate and number of replication cycles, and so these 
two factors are not important to the AZT-induced enhancement of mutation 
frequency. The reverse mutation rate will be considerably lower than the forward 
rate, owing to the fact that HR mutants are a minor fraction of the population; 
thus it will contribute little. Therefore, the AZT-induced increase in mutation 
frequency is most likely due to an enhancement of the mutation rate by AZT.
We cannot be certain that the other drugs tested, ddl and ddC, are not
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mutagenic, since it is possible that they exert and effect that is below our level of 
detection. Nevertheless, it is clear that AZT is much more mutagenic than these 
other antivirals to FIV.
The mutagenicity of AZT was at subinhibitory concentrations of AZT. We 
believe there would be even more mutagenicity at higher levels. We also believe 
that studies performed at these low drug levels are relevant to the clinical use of 
AZT. It is clear that patients are exposed to concentrations that inhibit HIV-1 
replication only partly, or at subtherapeutic levels, during periods of therapy. The 
dose of AZT used in humans is three- to six-fold lower than was suggested from 
early pharmacokinetic studies, and trough levels of AZT are considerably below 
the minimum inhibitory concentration of the drug (34,35). Virus that is 
replicating, albeit at a reduced rate, during these periods of exposure to low AZT 
concentrations may have an enhance mutation rate.
We do not know the mechanism of this AZT-induced mutagenesis. AZT 
has been shown to cause alterations in levels of DNA precursors (dNTPs)
(36,37), presumably due to effects of AZTMP on thymidylate kinase (38). It is 
well established that dNTP pool imbalances can enhance mutation rates of 
cultured cells (39). It is possible that the reverse transcriptase-catalyzed 
replication of retroviruses is particularly sensitive to pool imbalances owing to 
the lack of an associated exonuclease to carry out an editing function. It is also 
possible that the mutagenicity of AZT results from an effect of AZTTP directly on 
RT or is an indirect result of the incorporation of this analog into DNA (and 
attempted repair). It is also possible that the apparent mutagenic effects of
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BUdR and AZT are due to selection of HR variants rather than mutagenic 
effects. However, we believe it is unlikely in view of the well-known mutagenic 
properties of BUdR (30). Moreover, AZT-resistant mutants of FIV do not display 
an HR phenotype (data not shown).
The HR system we have developed with FIV is conceptually similar to 
phage genetic systems, and we believe that it will be important for studies on 
variability and fidelity of replication of a lentivirus. Our initial goal in development 
of this system was to obtain a genetic marker independent of the reverse 
transcriptase-encoding region of the pol gene. We would like to use this system 
to identify pol mutants of FIV that have mutator or antimutator phenotypes. We 
have already determined that the FIV RT has a low fidelity, similar to that 
reported for the HIV-1 RT (Garvey et al., unpublished observations). We also 
have a large number of FIV variants containing pol mutations that were selected 
as drug-resistant mutants. The systems we have developed will be used to 
determine how alterations of fidelity at the enzyme level correlate with mutation 
rates during virus replication.
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FIGURE LEGENDS 
FIG. 1. Effects of passage of CrFK cells on susceptibility to FIV infection. 
Susceptibility of these cells to infection by FIV was determined by FIA. The 
same cell-free virus stock was used to infect all of the preparations of CrFK cells. 
The infectivities of FIV Petaluma (▲) and 34TF10 (■) were determined as a 
function of increasing passage number. Each value represents an average of at 
least four determinations.
FIG. 2. Mutation frequency of FIV grown in the presence of a mutagen or 
antiviral drugs. CrFK cells were infected with wild-type FIV Petaluma (▲) or FIV 
34TF10 (■) in the presence of indicated concentrations of BUdR (A), AZT (B), 
ddl (C), and ddC (D). Mutation frequencies in the absence of drugs were 
0.0050±0.0003 for FIV Petaluma and 0.0057±0.0003 for FIV 34TF10. The 
mutation frequency value seen here for FIV Petaluma is slightly different from 
what is seen in Table 1, owing t the fact that these assays were performed using 
a different stock of virus. It has been found that different stocks of virus have 
slightly different background levels of HR mutants. Each value represents two or 
more experiments with at least four determinations per experiment. The error 
bars represent the standard error of the mean.
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TABLE 1 . P LA T IN G  E F F IC IE N C Y  O F  W ILD -TY P E  FIV  O N  S IN G L E -C E L L  C L O N E S  
O F  F IV -R ESTR IC TIVE C rF K  C E L L S '
C rF K  C L O N E 1- • P L A T IN G  E F F IC IE N C Y *
1 7 . 8 x 1  O '3
2 < 4 . 4  x  1 O '4
3 4 . 3  x  1 0 '2
4 2 . 6 x 1  O '3
5 2 . 6  x  1 0 '3
6 < 4 . 4  x  lO '4
7 8 . 7 x 1  O '3
9 2 .1  x l O ' 3
1 0 < 4 . 4  x  1 0 '4
11 < 4 . 4 x 1  O'4
1 2 < 4 . 4 x 1  O’4
1 3 § 1 .4  ±  0 . 4  x  1 0
1 4 < 4 . 4 x 1  O'4
1 5 4 . 4  x  1 0 ‘4
1 6 < 4 . 4  x  1 0 *4
1 7 1 . 4 x  1 0 '2
1 8 < 4 . 4  x  1 O'4
1 9 1 .7  x  1 0 '3
2 0 1 . 9 x 1  O '2
'  This t a b l e  r e p r e s e n ts  t h e  in it ia l s c r e e n in g  o f  a ll  o f  t h e  c lo n e s ,  
l i m i t e d  d ilu t io n s  o f  a  p o p u la t io n  o f  F IV -re s tr ic t iv e  C rF K  c e l ls  w e r e  u s e d  
t o  is o la te  s in g le  c e l l  c lo n e s .
*B y  d i f f e r e n t ia l ly  p la t in g  c e l l - f r e e  F IV  P e t a lu m a  o n  t h e  re s tr ic t iv e  c lo n e s  
a n d  o n  t h e  F IV -p e rm is s iv e  C rF K  c e lls ,  p la t in g  e f f i c i e n c y  o f  t h e  v irus  w a s  
o b t a i n e d  b y  d iv id in g  t h e  n u m b e r  o f  f o c i  d e t e c t e d  o n  re s tr ic t iv e  c e lls  b y  
t h e  n u m b e r  o f  f o c i  d e t e c t e d  o n  t h e  F IV -p e rm is s iv e  C rF K  c e lls .
§C l o n e  C rF K -1 3  w a s  s e l e c t e d  fo r  fu r th e r  e x p e r im e n t s  a n d  u s e d  fo r  t h e  
d e v e l o p m e n t  o f  t h e  h o s t  r a n g e  s y s te m . T h e  s t a n d a r d  e r ro r  o f  t h e  m e a n  
f r o m  m o r e  t h a n  f iv e  e x p e r im e n t s  is in d ic a t e d ._ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
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TABLE 2 .  RELATIVE P L A T IN G  E F F IC IE N C IE S  O F  H O S T -R A N G E  (H R ) M UTANTS  
V iru s '  PLAT. E F F IC .* F O L D  IN C R E A S E 5
P e t a lu m a 0 . 0 0 1 4  ±  0 . 0 0 0 4 * I X
HR1 0 . 0 3 9  ±  0 . 0 0 7 2 8 X
H R 2 0 . 0 2 7  ±  0 . 0 1 0 1 9 X
H R 3 0 . 1 8  ±  0 . 0 3 4 1 2 9 X
H R 4 0 . 0 7 2  ±  0 . 0 1 4 5 1 X
H R 5 0 . 1 6  ±  0 . 0 5 9 1 1 4 X
H R 6 0 . 0 4 2  ±  0 . 0 0 8 3 0 X
* E a c h  p o t e n t ia l  m u t a n t  w a s  is o la t e d  f r o m  a  s in g le  f o c u s  f o r m e d  o n  
C r F K -1 3  c e lls .
* P la t in g  e f f ic ie n c ie s  o f  t h e  H R  m u t a n t s  w e r e  d e t e r m i n e d  b y  d iv id in g  t h e  
n u m b e r  o f  f o c i  s e e n  o n  C R F K -1 3  c e lls  b y  t h e  n u m b e r  o f  f o c i  s e e n  o n  
F IV -p e rm is s iv e  C rF K  c e l ls .  E a c h  v a l u e  r e p r e s e n ts  t h e  re s u lts  o f  tw o  o r  
m o r e  e x p e r im e n t s  w ith  a t  le a s t  f o u r  d e t e r m in a t io n s  p e r  e x p e r im e n t .
* S t a n d a r d  e r ro r  o f  t h e  m e a n .
§ In c r e a s e d  e f f i c i e n c y  o f  in f e c t io n  o f  HR m u t a n t s  o n  F IV -re s tr ic t iv e  c e lls  
a s  c o m p a r e d  t o  t h e  c o n t r o l ,  F IV  P e t a lu m a .
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Chapter 7
Conclusions
By utilizing the host range system of the FIV model, it has been 
determined that AZT is mutagenic to FIV. The mutagenicity of AZT to FIV is 
nearly as high as the well-characterized mutagen, BUdR. However, two other 
RT inhibitors, ddl and ddC, tested negative for mutagenicity to FIV with this 
system. The mutagenicity of AZT could have major implications for AIDS 
chemotherapy, although it is not clear whether an increase in the mutation 
frequency of the virus would be beneficial or detrimental. If there was an 
increase in the frequency of lethal mutations during replication, it may contribute 
to the antiviral activity of the drug. However, it is likely that the enhanced 
mutation rate would contribute to mutations involved in genetic variation, evasion 
of the immune system, and changes in cell tropism. If pathogenesis is 
dependent upon accumulation of multiple mutations, AZT therapy could 
potentially alter the rate of pathogenesis.
The FIV host range system will be important for studying the variability 
and fidelity of the replication of the lentivirus. It can be utilized to identify pol 
mutations with antimutator and mutator phenotypes. There are a number of drug 
resistant mutants with known pol mutations available and can be evaluated for 
these phenotypes. This system can also be used to determine how alterations of 
fidelity at the enzyme level correlate with the mutation rates during viral 
replication. In addition, this system can also be used to evaluate the mutagenic
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effect of new antiviral drugs being developed (or drug combination) for AIDS 
chemotherapy.
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